BioSpace News Archive

- Reduces biohazard exposure for clinical staff - Built-in magnifying window for easy visualization - Compact tray that fits inside most specimen jars

Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason , M.D., Ph.D. will present virtually at the 39 th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST . Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative

Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection

Immune Therapeutics, Inc. (Ticker: IMUN) announced today that Cytocom, Inc., a company that spun-off from Immune in 2014, is participating in Biotech Showcase Digital and H.C. Wainwright BioConnect. Both events will be held virtually and are scheduled alongside the J.P. Morgan 39th Annual Healthcare Conference 2021. Details of the events are as follows: Biotech Showcase Digital Date: January 11-15, 2021 Registration: https://informaconnect.

BioAesthetics Corporation today announced that it has doubled its initial Series A funding goal of $2.5 million, closed on Dec. 30, 2020, at $5 million to commercialize its NACgraft TM biologic matrix— a regenerative nipple graft for breast cancer survivors. BioAesthetics’ Series A was co-led by FemHealth Ventures and personally by BioAesthetics’ Director Sandra Coufal, MD

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) (“BioMark”) is glad to announce Alfred Berkeley as a new member of the BioMark’s Advisory team, as he will be providing strategic and financial advice to help expand the company’s commercialization effort in the U.S.

Komodo Health today announced its acquisition of Mavens, a leader in cloud-based technology solutions.

Stakeholders have upped their investments in wound care biologics market share as the healing of wounds has gained impetus in the past several years.

A study of regulatory restrictions associated with the global surrogacy market unfolds that surrogacy is strictly not permitted in eight countries in Europe, even though it is tolerated in some others on account of lack of relevant laws.

Rising healthcare spending, increasing cancer cases, growing elderly population, and adoption of automated systems are the vital factors driving the growth of global tissue diagnostics market.